V Consent of applicants/manufacturers of a vaccine or a pharmaceutical product, diagnostics and vaccines for WHO to share information with the national regulatory authority(ies) confidentially in Emergency Situations DOCX
ID IVD M V VCP Impact assessment of WHO prequalification and systems supporting activities (June 2019) PDF
ID IVD IS M V VCP Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers 18–21 September 2017: Agenda PDF
ID IVD M V VCP Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers 2–5 December 2019: Agenda PDF
V Recommandation pour l'utilisation d'urgence (Procédure EUL) du nouveau Vaccin Antipoliomyélitique Oral de Type 2 (nVPO2) de PT Biofarma (Persero) (Traduction de la version anglaise publiée le 01 Décembre 2020) PDF
V Recommendation for an Emergency Use Listing (EUL) of Novel Oral Polio Vaccine Type 2 (nOPV2) submitted by PT BioFarma (Persero) - (Published 01 December 2020) PDF
V Recommendation for an Emergency Use Listing (EUL) of Tozinameran (COVID-19mRNA Vaccine (Nucleoside Modified)) submitted by BioNTech Manufacturing GmbH PDF
V Recommendation for an Emergency Use Listing of COVID-19 mRNA Vaccine (nucleoside modified) submitted by Moderna Biotech (Spain) PDF
V Recommendation for an Emergency Use Listing of COVID-19 Vaccine Janssen Submitted by Janssen – Cilag International N. V. (Belgium) PDF
V Roadmap for introduction and roll-out of Janssen VAC52150 (Ad26.ZEBOV, MVA-BN®-Filo) Ebola Virus Disease vaccine in African countries PDF
V Roadmap for introduction and roll‐out of Merck rVSV‐ZEBOV Ebola Virus Disease vaccine in African countries PDF
V Terms of Reference for the Technical Advisory Group on Snake Antivenom Immunoglobulin Listing (TAG-SAIL) PDF